You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
SARS-CoV-2 has dominated most discussions about laboratory shortages during the pandemic, but facilities have also struggled to secure supplies for more routine testing.
MicroGem is developing a PCR-based SARS-CoV-2 saliva test designed to detect SARS-CoV-2 at the point-of-care with results in 15 minutes.
The device also has Emergency Use Authorization from the US Food and Drug Administration and has CE marking for in vitro diagnostic use.
DNA Script will build a prototype qPCR probe manufacturing platform that can be used in the rapid development of biothreat diagnostics.
The medical director of lab information technology at Yale-New Haven Hospital, Durant has published a paper on information sharing challenges during the pandemic.
Ortho said it intends to use the net proceeds from the offering to redeem senior notes and repay borrowings under its dollar term loan facility, among other uses.
Within its diagnostics division, the firm posted molecular diagnostics revenue of $995.3 million, up more than fivefold from $178.5 million in fiscal Q1 2020.
The company emphasized on its earnings call that decentralization of laboratory testing is a key component of its long-term strategy.
The firm is also developing an instrument-free molecular diagnostic assay technology for the home testing market.
The firm also announced the amendment of the terms of a loan with CRG, a global healthcare investor.
The firm said it saw a significant contribution from pandemic-related products including €130 million in revenue from its rapid antigen test.
The test uses primers and probes from Thermo Fisher Scientific's authorized TaqPath COVID-19 Combo Kit with a modified results interpretation algorithm.
Todos said it intends to use part of the proceeds to retire outstanding convertible notes and complete the acquisition of Provista Diagnostics.
Talis, a point-of-care test developer, said that the principal purpose for the offering is to obtain additional capital to support its operations, among other purposes.
The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.
Rhinostics said it plans to purse Emergency Use Authorization from the FDA for the swab for home collection with PCR testing.
FIND said it will announce agreements that will enable the distribution of more than 250 million rapid antigen tests per year to low- and middle-income countries.
Molzym said a new analytic platform, called AutoSepT, would enable fast pathogen identification directly from specimens in less than five hours.
Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
The administration has proposed steps such as funding increased production of testing supplies and ensuring schools have access to more frequent testing.